3 results
Approved WMOCompleted
Primary objective: To demonstrate a clinically significant improvement in morning FEV1 in moderate to severe allergic asthmatics inadequately controlled by ICS therapy treated with QAW039 for 12 weeks compared to placebo.Secondary objectives:…
Approved WMOWill not start
To compare the efficacy of fesoterodine to placebo and tolterodine ER in subjects with overactive bladder after 12 weeks of treatment.
Approved WMOPending
Primary Objective:To validate the ExSpiron©, a device for non-invasive monitoring of respiratory volume in patients with ALS during spontaneous breathing and during NIV.Secondary Objective(s):• to observe the difference between nocturnal respiration…